These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8285738)

  • 21. Clinical features of eosinophilia myalgia syndrome and related disorders.
    Clauw DJ
    Adv Exp Med Biol; 1996; 398():331-8. PubMed ID: 8906285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The eosinophilia-myalgia syndrome and eosinophilic fasciitis.
    Jimenez SA; Varga J
    Curr Opin Rheumatol; 1991 Dec; 3(6):986-94. PubMed ID: 1772754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.
    Martínez-Cabot A; Messeguer A
    Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome.
    Kilbourne EM; Posada de la Paz M; Abaitua Borda I; Diez Ruiz-Navarro M; Philen RM; Falk H
    J Am Coll Cardiol; 1991 Sep; 18(3):711-7. PubMed ID: 1869734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients.
    Alonso-Ruiz A; Calabozo M; Perez-Ruiz F; Mancebo L
    Medicine (Baltimore); 1993 Sep; 72(5):285-95. PubMed ID: 8412642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The toxic oil syndrome: 20 years on.
    Diggle GE
    Int J Clin Pract; 2001; 55(6):371-5. PubMed ID: 11501225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of types I, III and IV collagen genes in fibrotic skin and nerve lesions of toxic oil syndrome patients.
    Gomez-Reino JJ; Sandberg M; Carreira PE; Vuorio E
    Clin Exp Immunol; 1993 Jul; 93(1):103-7. PubMed ID: 8391940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Of faddism, toxic oil, and scleroderma.
    Berry CL
    J Pathol; 1993 Aug; 170(4):419-20. PubMed ID: 8410491
    [No Abstract]   [Full Text] [Related]  

  • 29. The toxic oil syndrome: a continuing challenge.
    Diggle GE
    Adverse Drug React Toxicol Rev; 1995; 14(1):11-35. PubMed ID: 7612780
    [No Abstract]   [Full Text] [Related]  

  • 30. Cutaneous toxic mucinoses.
    Rongioletti F; Rebora A
    J Am Acad Dermatol; 1992 May; 26(5 Pt 1):789-90. PubMed ID: 1583189
    [No Abstract]   [Full Text] [Related]  

  • 31. 1995 Bailey K. Ashford lecture. Public health lessons from two catastrophic epidemics: the toxic oil syndrome and the eosinophilia-myalgia syndrome.
    James TN
    P R Health Sci J; 1996 Mar; 15(1):45-8. PubMed ID: 8744866
    [No Abstract]   [Full Text] [Related]  

  • 32. Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome.
    Smith SA
    Adv Exp Med Biol; 1996; 398():359-64. PubMed ID: 8906289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism.
    del Pozo V; de Andrés B; Gallardo S; Cárdaba B; de Arruda-Chaves E; Cortegano MI; Jurado A; Palomino P; Oliva H; Aguilera B; Posada M; Lahoz C
    Toxicology; 1997 Mar; 118(1):61-70. PubMed ID: 9074654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report.
    Philen RM; Posada M
    Semin Arthritis Rheum; 1993 Oct; 23(2):104-24. PubMed ID: 8266108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the pathology of fascia in eosinophilic myalgia syndrome patients and idiopathic eosinophilic fasciitis.
    Umbert I; Winkelmann RK; Wegener L
    Dermatology; 1993; 186(1):18-22. PubMed ID: 8435512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Skin manifestations of toxic syndrome due to denatured rapeseed oil].
    Fonseca E
    Actas Dermosifiliogr; 2009 Dec; 100(10):857-60. PubMed ID: 20038361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AHR activation by tryptophan--pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome?
    Rieber N; Belohradsky BH
    Immunol Lett; 2010 Feb; 128(2):154-5. PubMed ID: 19941898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased type I collagen gene expression in L-tryptophan associated eosinophilia-myalgia syndrome skin fibroblasts.
    Varga J; Li L; Jimenez SA
    J Rheumatol; 1993 Aug; 20(8):1303-8. PubMed ID: 8230009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The toxic oil syndrome (TOS, 1981): from the disease towards a toxicological understanding of its chemical aetiology and mechanism.
    Aldridge WN
    Toxicol Lett; 1992 Dec; 64-65 Spec No():59-70. PubMed ID: 1471212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.